Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Chris Lange | May 2, 2018 at 8:45 AM EDT

Why Gilead Sciences Whiffed in Q1

Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.

Chris Lange | May 1, 2018 at 12:05 PM EDT

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since…

Chris Lange | Apr 25, 2018 at 8:40 AM EDT

Major Biotechs Face Rising Tide of Short Interest

The April 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Apr 11, 2018 at 9:05 AM EDT

Short Sellers Back Way Off Major Biotechs

The March 29 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 27, 2018 at 9:30 AM EDT

Major Biotechs See Rising Tide in Short Interest

The March 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 12, 2018 at 9:45 AM EDT

Major Biotechs: Tough Call for Short Sellers

The February 28 short interest data have been compared with the previous report, and short interest moves in the selected…

Lee Jackson | Mar 9, 2018 at 10:05 AM EST

5 Top Jefferies Health Care Picks Have Big-Time Potential

These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios.…

Chris Lange | Feb 28, 2018 at 9:15 AM EST

Major Biotechs Continue to See a Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech…

Trey Thoelcke | Feb 23, 2018 at 10:20 AM EST

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will…

Jon C. Ogg | Feb 22, 2018 at 2:52 PM EST

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.

Chris Lange | Feb 22, 2018 at 10:20 AM EST

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into…

Lee Jackson | Feb 14, 2018 at 8:10 AM EST

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time…

Chris Lange | Feb 12, 2018 at 9:15 AM EST

Major Biotechs See Rising Tide of Short Interest

The January 31 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Feb 8, 2018 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

The top analyst upgrades, downgrades and other research calls from Thursday include Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn,…

Chris Lange | Feb 4, 2018 at 10:25 AM EST

Disney, Tesla, Twitter and More Earnings Coming This Week

24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report…

1 … 16 17 18 19 20 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Gilead Sciences Whiffed in Q1

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Major Biotechs Face Rising Tide of Short Interest

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Major Biotechs: Tough Call for Short Sellers

5 Top Jefferies Health Care Picks Have Big-Time Potential

Major Biotechs Continue to See a Rising Tide of Short Interest

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Major Biotechs See Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

Disney, Tesla, Twitter and More Earnings Coming This Week

United States Antimony Jumps 8% on $100M Buyback, USA Rare Earth Slips, MP Materials Holds Flat

Wendy’s Jumps 5% on Nelson Peltz Take-Private Report, COO Role Revival

Bessent Just Doubled Treasury’s Bond-Buying Program. Here’s What It Means For Your Retirement Account And Your Mortgage.

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.

United States Antimony Jumps 8% on $100M Buyback, USA Rare Earth Slips, MP Materials Holds Flat

Wendy’s Jumps 5% on Nelson Peltz Take-Private Report, COO Role Revival

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Gilead Sciences Whiffed in Q1

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Major Biotechs Face Rising Tide of Short Interest

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Major Biotechs: Tough Call for Short Sellers

5 Top Jefferies Health Care Picks Have Big-Time Potential

Major Biotechs Continue to See a Rising Tide of Short Interest

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Major Biotechs See Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

Disney, Tesla, Twitter and More Earnings Coming This Week

United States Antimony Jumps 8% on $100M Buyback, USA Rare Earth Slips, MP Materials Holds Flat

Wendy’s Jumps 5% on Nelson Peltz Take-Private Report, COO Role Revival

Bessent Just Doubled Treasury’s Bond-Buying Program. Here’s What It Means For Your Retirement Account And Your Mortgage.

Featured Reads

Company Stock in a 401(k) Gets a Special Tax Break. One Standard Rollover Erases It Forever.

He Worked 600 Hours of Wildfire Overtime at 64. He Thought the New Tax Break Would Protect His Social Security Check. He Was Wrong.